Print this page
 Email this page

 Connect with UMMC on:
 Twitter
 Facebook
 YouTube
iPhone

 Share this page:

Bookmark and Share

Home > Medical Reference > Encyclopedia (English)

Toggle: English / Spanish

 

Video details

[ Flash player icon ] Please install flash player to see this video.

Hospital Virtual Tour

Click to take a virtual tour

Related Content


 

Hunter syndrome - Overview

Alternative Names

Mucopolysaccharidosis type II, Iduronate sulfatase deficiency

Definition of Hunter syndrome:

Hunter syndrome is a hereditary disease in which the breakdown of a mucopolysaccharide (a chemical that is widely distributed in the body outside of cells) is defective. This chemical builds up and causes a characteristic facial appearance, abnormal function of multiple organs, and in severe cases, early death.

Causes, incidence, and risk factors:

Hunter syndrome is inherited as an X-linked recessive disease. This means that boys will be the ones most often affected, because the defective gene is on the X chromosome. Boys have only 1 copy of the X chromosome. Girls have 2 copies.

Because girls have two X chromosomes, their normal copy on one X can provide a functioning gene, even if their other X has the abnormal gene. Women can carry the defective gene and pass it on, without being affected themselves, unless both their copies are abnormal. But because boys have an X and a Y, there is no normal X gene to fix the problem if the X is defective.

The metabolic abnormality that causes Hunter syndrome is a lack of the enzyme iduronate sulfatase. Without this enzyme, mucopolysaccharides collect in various body tissues, causing damage.

Affected children may develop an early-onset type (severe form) shortly after age 2 that causes a large skull, coarse facial features, profound mental retardation, spasticity, aggressive behavior, joint stiffness, and death before age 20. A late-onset type (mild form) causes later and less severe symptoms.

  • Reviewed last on: 9/28/2007
  • David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc. Previously reviewed by Brian Kirmse, MD, Mount Sinai School of Medicine, Department of Human Genetics, New York, NY. Review provided by VeriMed Healthcare Network (8/11/2006).

References

Muenzer J, Wraith JE, Beck M, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med. 2006 Aug;8(8):465-73.

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.
adam.com